Glucose-lowering pharmacotherapies in Chinese adults with type 2 diabetes and cardiovascular disease or chronic kidney disease. An expert consensus reported by the Chinese Diabetes Society and the Chinese Society of Endocrinology

Citation
Hong T, Su Q, Li X, et al. Diabetes Metab Res Rev 2020; epub ahead of press.